Intellia Therapeutics Up 7%

Intellia Therapeutics was up over 7% in morning trade Wednesday after it reported updated data showing increased levels of genome editing efficiency in vivo and durability results with its CRISPR/Cas9 technology, following a single administration.

Using its lipid nanoparticle (LNP) technology, Intellia achieved approximately a 97% reduction in serum transthyretin (TTR) protein driven by 70 percent gene editing efficiency in the mouse liver.

“These results are extremely promising, as they demonstrate compelling activity with lipid nanoparticles observed in the liver following a single dose,” said Executive Vice President, R&D John Leonard, M.D. “We are excited by the extent of the effect, which confirms the power of CRISPR/Cas9 for potential therapeutic uses.”

By Bucky Rini